{"disease":{"id":"recurrent-breast-carcinoma","name":"recurrent breast carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01275677","title":"Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3270,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05564377","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":2900,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06217874","title":"Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT00785291","title":"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":799,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02115282","title":"Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":608,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03418961","title":"S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":491,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT00601900","title":"Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":394,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02595905","title":"Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":344,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03737695","title":"Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer","phase":"","overall_status":"SUSPENDED","enrollment_count":300,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT00390455","title":"Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":295,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04022772","title":"Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":287,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03199885","title":"Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":190,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04297384","title":"Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice","phase":"NA","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT02415387","title":"Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":172,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":true},{"nct_id":"NCT02208375","title":"mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":159,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01552434","title":"Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":155,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03971409","title":"Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":145,"lead_sponsor_name":"Laura Huppert, MD, BA","has_results":false},{"nct_id":"NCT01622868","title":"Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":143,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03154190","title":"Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Stanford University","has_results":true},{"nct_id":"NCT07474090","title":"Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":false},{"nct_id":"NCT01286987","title":"Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT00892736","title":"Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":98,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01908101","title":"Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT02311933","title":"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":81,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02411656","title":"Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":71,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03281902","title":"Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":68,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT00684983","title":"Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01730833","title":"Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":63,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT01327781","title":"Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":62,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06704659","title":"Study on Recurrent Breast Cancer and Repeated Radiation Therapy","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Turku University Hospital","has_results":false},{"nct_id":"NCT01349959","title":"Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05274451","title":"A Study to Investigate LYL797 in Adults With Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false},{"nct_id":"NCT03530696","title":"T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"University of Arizona","has_results":true},{"nct_id":"NCT04521764","title":"A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03602079","title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT00699491","title":"Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01145430","title":"Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02996825","title":"Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT01251874","title":"Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":44,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04052555","title":"Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":42,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01624441","title":"Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01463072","title":"Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT01638533","title":"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01434303","title":"Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01964924","title":"Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03202316","title":"Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":37,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02152943","title":"Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04550494","title":"Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02370264","title":"Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer","phase":"NA","overall_status":"TERMINATED","enrollment_count":36,"lead_sponsor_name":"University of Southern California","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}